Published in Ann Surg on September 01, 1988
The differentiation and function of human T lymphocytes. Cell (1980) 11.88
Monoclonal antibodies defining distinctive human T cell surface antigens. Science (1979) 10.50
Antigen recognition by human T lymphocytes is linked to surface expression of the T3 molecular complex. Cell (1982) 4.86
Does OKT3 monoclonal antibody react with an antigen-recognition structure on human T cells? Proc Natl Acad Sci U S A (1981) 3.09
Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation (1981) 2.22
Survival following cardiac transplantation--what are acceptable standards? West J Med (1987) 1.47
Human in vivo antigenic modulation induced by the anti-T cell OKT3 monoclonal antibody. Eur J Immunol (1982) 1.37
Treatment of refractory cardiac allograft rejection with OKT3 monoclonal antibody. Am J Med (1987) 1.34
Serial transvenous biopsy of the transplanted human heart. Improved management of acute rejection episodes. Lancet (1974) 1.07
Reduction of infectious complications following heart transplantation with triple-drug immunotherapy. J Heart Transplant (1987) 0.95
The use of OKT3 for stubborn heart allograft rejection: an advance in clinical immunotherapy? J Heart Transplant (1988) 0.92
Use of Orthoclone OKT3 monoclonal antibody in cardiac transplantation: early experience with rejection prophylaxis and treatment of refractory rejection. Transplant Proc (1987) 0.88
Feasibility of discontinuation of corticosteroid maintenance therapy in heart transplantation. J Heart Transplant (1987) 0.83
Therapeutic use of monoclonal antibodies in kidney transplantation. Adv Nephrol Necker Hosp (1985) 0.80
Heart allograft rejection under varying immunosuppressive protocols as evaluated by endomyocardial biopsy. J Heart Transplant (1987) 0.78
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med (1996) 12.77
Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med (1982) 6.79
Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med (2001) 3.44
Increased protein kinase C activity and expression of Ca2+-sensitive isoforms in the failing human heart. Circulation (1999) 3.35
Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet (1993) 3.20
Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation (1996) 3.14
Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol (1995) 3.12
Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy. Lancet (1993) 3.10
Myosin heavy chain isoform expression in the failing and nonfailing human heart. Circ Res (2000) 3.08
Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep (1978) 2.63
Transforming growth factor-beta1 induces Nox4 NAD(P)H oxidase and reactive oxygen species-dependent proliferation in human pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol (2005) 2.62
Congestive heart failure: fifty years of progress. Circulation (2000) 2.61
Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group. N Engl J Med (1993) 2.39
Myosin heavy chain gene expression in human heart failure. J Clin Invest (1997) 2.39
Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant (1994) 2.36
Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium. J Clin Invest (1997) 2.29
Unusual presentation of nickel allergy requiring explantation of an Amplatzer atrial septal occluder device. Clin Cardiol (2009) 2.07
Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. Circulation (1996) 2.01
Report of the National Heart, Lung, and Blood Institute Special Emphasis Panel on Heart Failure Research. Circulation (1997) 2.00
Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response. Circulation (1986) 1.97
Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications. J Heart Transplant (1990) 1.91
Multicenter clinical evaluation of the HeartMate 1000 IP left ventricular assist device. Ann Thorac Surg (1992) 1.88
Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart. J Clin Invest (1988) 1.85
Selective downregulation of the angiotensin II AT1-receptor subtype in failing human ventricular myocardium. Circulation (1997) 1.81
Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure. J Mol Cell Cardiol (2001) 1.70
Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep (1978) 1.68
Early anthracycline cardiotoxicity. Am J Med (1978) 1.63
Beta-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. J Clin Invest (1992) 1.59
Cardiac transplantation in situs inversus. J Thorac Cardiovasc Surg (1990) 1.59
Improved mortality and rehabilitation of transplant candidates treated with a long-term implantable left ventricular assist system. Ann Surg (1995) 1.56
Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. J Am Coll Cardiol (1998) 1.53
Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Circulation (1999) 1.52
Effects of carvedilol on systolic and diastolic left ventricular performance in idiopathic dilated cardiomyopathy or ischemic cardiomyopathy. Am J Cardiol (1996) 1.52
Surgical complications in bridging to transplantation: the Thermo Cardiosystems LVAD. Ann Thorac Surg (1992) 1.49
A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med (1992) 1.48
Coordinate changes in Myosin heavy chain isoform gene expression are selectively associated with alterations in dilated cardiomyopathy phenotype. Mol Med (2002) 1.47
Survival following cardiac transplantation--what are acceptable standards? West J Med (1987) 1.47
Heart and lung transplantation: autotransplantation and allotransplantation in primates with extended survival. J Thorac Cardiovasc Surg (1980) 1.47
Gastric emptying after gastric interposition for cancer of the esophagus or hypopharynx. Ann Thorac Surg (1991) 1.45
Myocardial-directed overexpression of the human beta(1)-adrenergic receptor in transgenic mice. J Mol Cell Cardiol (2000) 1.43
Selective gene expression in failing human heart. Quantification of steady-state levels of messenger RNA in endomyocardial biopsies using the polymerase chain reaction. Circulation (1991) 1.43
Regulation of the mRNA-binding protein AUF1 by activation of the beta-adrenergic receptor signal transduction pathway. J Biol Chem (1996) 1.42
Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation (1996) 1.41
Patch closure of the aortic anulus in a recipient of a ventricular assist device. J Thorac Cardiovasc Surg (2000) 1.39
Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. J Clin Invest (2001) 1.37
Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med (1978) 1.34
Treatment of refractory cardiac allograft rejection with OKT3 monoclonal antibody. Am J Med (1987) 1.34
Medicare-designated centers for cardiac transplantation. N Engl J Med (1987) 1.32
Regulation of thyroid hormone receptor isoforms in physiological and pathological cardiac hypertrophy. Circ Res (2001) 1.30
Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation (1989) 1.29
Histamine provocation of clinical coronary artery spasm: implications concerning pathogenesis of variant angina pectoris. Am Heart J (1981) 1.27
Quantitative pharmacologic responses of normal and atherosclerotic isolated human epicardial coronary arteries. Circulation (1984) 1.21
Effect of a resident self-study and presentation program on performance on the thoracic surgery in-training examination. Am J Surg (2001) 1.21
Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med (1983) 1.19
Study of the normal and failing isolated human heart: decreased response of failing heart to isoproterenol. Am Heart J (1983) 1.19
Differences in beta-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy. Circulation (1991) 1.17
Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail (1998) 1.17
Signaling pathways responsible for fetal gene induction in the failing human heart: evidence for altered thyroid hormone receptor gene expression. Circulation (2001) 1.17
Mitral and tricuspid valve rupture after moderate blunt chest trauma. Ann Thorac Surg (2000) 1.17
Management of refractory empyema with early decortication. Am J Surg (1988) 1.15
Beta-adrenergic function in heart muscle disease and heart failure. J Mol Cell Cardiol (1985) 1.15
Generating genetic risk scores from intermediate phenotypes for use in association studies of clinically significant endpoints. Ann Hum Genet (2005) 1.13
Sarcoplasmic reticulum-associated cyclic adenosine 5'-monophosphate phosphodiesterase activity in normal and failing human hearts. J Clin Invest (1991) 1.12
Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy. Cancer Treat Rep (1978) 1.10
Adriamycin cardiotoxicity: endomyocardial biopsy evidence of enhancement by irradiation. Am J Surg Pathol (1977) 1.10
The adrenergic nervous system in heart failure. N Engl J Med (1984) 1.09
Artificial circulatory support with textured interior surfaces. A counterintuitive approach to minimizing thromboembolism. Circulation (1994) 1.09
Successful treatment of a cardiac angiosarcoma with combined modality therapy. J Heart Lung Transplant (1995) 1.09
Acute and chronic cardiovascular effects of doxorubicin in the dog: the cardiovascular pharmacology of drug-induced histamine release. J Cardiovasc Pharmacol (1980) 1.09
Effects of carvedilol on right ventricular function in chronic heart failure. Am J Cardiol (1998) 1.09
Guillain-Barré syndrome following coronary artery bypass surgery. Am Heart J (1987) 1.08
Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. Am J Cardiol (1999) 1.08
Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am J Med (1990) 1.08
Mechanism of action of bucindolol in human ventricular myocardium. J Cardiovasc Pharmacol (1990) 1.07
Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity. Am Heart J (1983) 1.07
Histamine and the human heart: the other receptor system. Am J Cardiol (1982) 1.07
Cardiac-allograft survival in primates treated with cyclosporin A. Lancet (1979) 1.07
New method to evaluate myocyte remodeling from formalin-fixed biopsy and autopsy material. J Card Fail (1998) 1.07
Cardiac adrenergic receptor effects of carvedilol. Eur Heart J (1996) 1.06
Ca2+ uptake by cardiac sarcoplasmic reticulum from patients with idiopathic dilated cardiomyopathy. Circ Res (1989) 1.06
Studies with isolated human coronary arteries. Some general observations, potential mediators of spasm, role of calcium antagonists. Chest (1980) 1.06
Efficacy and cost of cardiac monitoring in patients receiving doxorubicin. Cancer (1982) 1.04
Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am Heart J (1981) 1.04
Effects of acute beta-adrenergic receptor blockade on age-associated changes in cardiovascular performance during dynamic exercise. Circulation (1994) 1.02
Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group. J Card Fail (1997) 1.02
Pharmacology and inotropic potential of forskolin in the human heart. J Clin Invest (1984) 1.01
Expression of alpha-subunits of G proteins in failing human heart: a reappraisal utilizing quantitative polymerase chain reaction. J Mol Cell Cardiol (1991) 1.01